Characterization of the selective in vitro and in vivo binding properties of crenezumab to oligomeric Aβ

BACKGROUND: Accumulation of amyloid β (Aβ) in the brain is proposed as a cause of Alzheimer’s disease (AD), with Aβ oligomers hypothesized to be the primary mediators of neurotoxicity. Crenezumab is a humanized immunoglobulin G4 monoclonal antibody that has been shown to bind to synthetic monomeric...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Alzheimers Res Ther
Glavni autori: Meilandt, William J., Maloney, Janice A., Imperio, Jose, Lalehzadeh, Guita, Earr, Tim, Crowell, Susan, Bainbridge, Travis W., Lu, Yanmei, Ernst, James A., Fuji, Reina N., Atwal, Jasvinder K.
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2019
Teme:
Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6886224/
https://ncbi.nlm.nih.gov/pubmed/31787113
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13195-019-0553-5
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items